Human papillomavirus seropositivity and risks of head and neck cancer (original) (raw)

Abstract

We examined antibody response to VLP HPV-16, HPV-16 E6 and E7 antibodies as potential seromarkers of HPV-related head and neck cancer (HNC). The study included 204 HNC cases and 326 controls evaluated for HPV presence in sera using ELISAs for anti-HPV VLP antibodies and HPV-16 E6 and/or E7 antibodies, and in tumor tissue using PCR and DNA sequencing. Anti-HPV-16 VLP was detected in 33.8% of cases and 22.4% of controls, anti-E6 in 20.6% of cases and 0.9% of controls and anti-E7 in 18.6% of cases and 0.6% of controls. HPV-16 DNA was detected in 26.1% of tumors. The adjusted risk of HNC was elevated among those seropositive for HPV-16 VLP (odds ratio (OR) 5 1.7, 1.1-2.5), E6 (OR 5 32.8,). Compared to HPV DNA-negative/seronegative cases, tumor HPV-16 cases had increased risk of detection with anti-VLP antibodies (OR 5 6.8, 3.1-14.9). The odds were more pronounced among cases seropositive for E6 (OR 5 69.0, 19.3-247) or E7 (OR 5 50.1, 14.7-171). Antibodies against E6 or E7 were associated with risk of cancer in the oral cavity (OR 5 5.1, 1.2-22.4) and oropharynx (OR 5 72.8,, and with disease characteristics: stage, grade and nodal status. Anti-E6 and/or E7 antibodies were found in 74% of tumor HPV-16 positive cases but in only 5% of tumor HPV-negative cases (K 50.7, 0.6-0.8) suggesting good correlation between the serologic marker and HPV tumor status. Antibodies to HPV-16 E6 and/or E7 represent a more specific biomarker than anti-HPV-16 VLP of an HPV-related HNC. Because of the survival advantage of HPV-related HNC, HPV-16 E6/E7 detection may be useful in therapy targeted for HPV-related tumors. '

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (38)

  1. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, Haugen TH, Turek LP. Age sexual behavior and human pap- illomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004;104:336-44.
  2. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavi- rus types in head and neck squamous cell carcinomas worldwide: a sys- tematic review. Cancer Epidemiol Biomarkers Prev 2005;191:467-75.
  3. Franco EL, Schlecht F, Saslow D. The epidemiology of cervical can- cer. Cancer J 2003;9:348-59.
  4. Nonnenmacher B, Kruger Kjaer S, Svare EI, Scott JD, Hubbert NL, van den Brule AJ, Kirnbauer R, Walboomers JM, Lowy DR, Schiller JT. Seroreactivity to HPV16 virus-like particles as a marker for cervical can- cer risk in high-risk populations. Int J Cancer 1996;68:704-9.
  5. Wang ZH, Kjelberg L, Abdalla H, Wiklund F, Eklund C, Knekt P, Lehtinen M, Kallings I, Lenner P, Hallmans G, Mahlck CG, Wadell G et al. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J Infect Dis 2000;181: 456-62.
  6. Sigstad E, Lie AK, Luostarinen T, Dillner J, Jellum E, Lehtinen M, Thoresen S, Abeler V. A prospective study of the relationship between prediagnostic human papillomavirus seropositivitiy and HPV DNA in subsequent cervical carcinomas. Br J Cancer 2002;87:175-80.
  7. Sun Y, Eluf-Neto J, Bosch FX, Munoz N, Booth M, Walboomers JM, Shah KV, Viscidi RP. Human papillomavirus-related serological markers of invasive cervical carcinoma in Brazil. Cancer Epidemiol Biomarkers Prev 1994;3:341-7.
  8. Gissmann L. Immunologic responses to human papillomavirus infec- tion. Obstet Gynecol Clin North Am 1996;23:625-39.
  9. Jochmus-Kudierlka I, Schneider A, Braun R, Kimmig R, Koldovsky U, Schneweis KE, Seedorf K, Gissmann L. Antibodies against the human papillomavirus type 16 early proteins in human sera: correla- tion of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989;81:1698-1704.
  10. Sun Y, Eluf-Neto J, Bosch FX, Munoz N, Walboomers JM, Meijer CJ, Shah KV, Clayman B, Viscidi RP. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervi- cal carcinoma. Cancer Epidemiol Biomarkers Prev 1999;8:935-40.
  11. Anders H, Rosenbauer J, Matiaske B. Reprasentative verzehrstudie in der Bundesrepublik Deutschland inclu. West-Berlin. In: Schriften- reithe der AGEV. Band 8. 1990.
  12. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernandez L, Idris A et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer Multicenter Study. J Natl Cancer Inst 2003;95:1772-83.
  13. Meschede W, Zumbach K, Braspenning J, Scheffner M, Benitez-Bri- biesca L, Luande J, Gissmann L, Pawlita M. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998;36:475-80.
  14. Schwartz SM, Daling DR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Mao R-J, Fitzgibbons ED, Huang S, Beckmann AM, McDougall JK, Galloway DA. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90:1626-36.
  15. Zumbach K, Hoffmann M, Kahn T, Bosch F, Gottschlich S, Gorogh T, Rubert H, Pawlita M. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and- neck squamous-cell carcinoma. Int J Cancer 2000;85:815-18.
  16. American Joint Committee on Cancer. AJCC cancer staging man- ual,5th edn. Chicago, IL: Lippincott Williams and Wilkins, 1997.
  17. Smith EM, Ritchie JR, Summersgill KF, Hoffman HT, Wang DH, Haugen TH, Turek LP. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004;96:449-55.
  18. Summersgill KF, Smith EM, Kirchner HL, Haugen TH, Turek LP. p53 Polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:334-9.
  19. Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Junge- huelsing M, Eckel HE, Dienes HP, Pfister HJ, Fuchs PG. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in ton- sillar carcinomas. Cancer 2001;92:2875-84.
  20. Chehab FF, Doherty M, Cai SP, Kan YW, Cooper S, Rubin EM. Detection of sickle cell anaemia and thalassaemias [letter]. Nature 1987;329:293-4.
  21. Ting Y, Manos MM. Detection and typing of genital human papillo- maviruses. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR protocols, a guide to methods and applications. Berkeley, CA: Academic Press, 1990.356-67.
  22. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, Rush BB et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
  23. de Roda Husman A-M, Walboomers JMM, van den Brule AJC, Meijer CJLM, Snijders PJF. The use of general primers GP5 and GP6 elongated at their 3 0 ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995;76:1057-62.
  24. Altschul SF, Madden TL, Schaeffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of pro- tein database search programs. Nucleic Acid Res 1997;25:3389-402.
  25. Hams ˇ ıkov a E, Ludv ıkov a V, Tachezy R, Kovar ˇ ık J, Br ˇous ˇkov a L, Vonka V. Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic. Int J Cancer 1998;77:689- 94.
  26. Sehr P, Zumbach K, Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 2001;253:153-62.
  27. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.88-91.
  28. Rosner B. Fundamentals of biostatistics. Boston, MA: PWS-Kent, 1990.170-175.
  29. SAS System for Windows, Version 8.2. Cary, NC: SAS Institute, 2001.
  30. Lehtinen M, Pawlita M, Zumbach K, Lie K, Hakama M, Jellum E, Koskela P, Luostarinen T, Paavonen J, Pukkala E, Sigstad E, Thoresen S et al. Evaluation of antibody response to HPV early proteins in women in whom cervical cancer developed one to 20 years later. Am J Obstet Gynecol 2003;188:49-55.
  31. Rosales R, Lopez-Contreras M, Corest RR. Antibodies against human papillomavirus (HPV) type 16 an 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA. J Med Virol 2001; 65:736-44.
  32. Mork J, Lie K, Glattre E, Hallmans G, Jellum E, Koskela P, Moller B, Purkala E, Schiller JT, Youngman L, Lehtinen M, Dillner J. Human papillomavirus infection as a risk factor for squamous cell carcinoma of the head and neck. N Engl J Med 2001;344:1125-31.
  33. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang DH, Klussmann JP, Turek LP, Haugen TH. Human papillomavirus infec- tion as a prognostic factor in carcinomas of the oral cavity and oro- pharynx. Int J Cancer 2003;104:336-44.
  34. Friesland S, Mellin H, Munck-Wikland E, Nilsson A, Lindholm J, Dalianis T, Lewensohn R. Human papilloma virus (HPV) and p53 im- munostaining in advanced tonsillar carcinoma-relation to radiother- apy response and survival. Anticancer Res 2001;21:529-34.
  35. Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, Hietanen S. Che- moradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depend- ing on the platinum carrier ligand. Cancer Res 2002;62:7364-71.
  36. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001;125:1-9.
  37. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Snyder DE, Shah KV, Sidransky D. Evidence for a causal association between human papil- lomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
  38. Carter JJ, Galloway DA. Humoral immune response to human papil- lomavirus infection. Clin Dermatol 1997;15:249-59.